ADXN
Addex Therapeutics LtdNASDAQHealthcare$5.72-8.93%ClosedMarket Cap: $3.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.81
P/S
46.57
EV/EBITDA
-0.70
DCF Value
$3.98
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14.1%
Operating Margin
-1789.2%
Net Margin
-4397.0%
ROE
-78.3%
ROA
-83.2%
ROIC
-40.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $29.7K | 100.0% | $-696.2K | $-1.6M | $-1.67 | — |
| Q2 2025 | $36.4K | -544.5% | $-732.9K | $-1.8M | $-2.40 | — |
| Q1 2025 | $0.00 | NaN% | $-606.3K | $-1.5M | $-1.80 | — |
| Q4 2024 | $1.5K | 100.0% | $-445.6K | $-1.2M | $-1.48 | — |
| FY 2024 | $404.1K | 100.0% | $-2.8M | $7.1M | $8.40 | — |
| Q3 2024 | $53.8K | 100.0% | $-622.2K | $-1.5M | $-1.88 | — |
| Q2 2024 | $115.3K | 100.0% | $-899.3K | $12.9M | $15.60 | — |
| Q1 2024 | $233.5K | 100.0% | $-788.1K | $-3.1M | $-3.80 | — |
| Q4 2023 | $153.5K | 100.0% | $-2.7M | $-2.9M | $-3.60 | — |
| FY 2023 | $1.6M | 100.0% | $-2.2M | $-10.6M | $-16.80 | — |
| Q3 2023 | $327.7K | 100.0% | $-749.2K | $-2.6M | $-4.07 | — |
| Q2 2023 | $630.9K | 100.0% | $-396.2K | $-2.7M | $-4.45 | — |